Tiny trial tests Radiation-Immunotherapy cocktail for tough bile duct cancer
NCT ID NCT04708067
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of focused radiation and an immunotherapy drug called bintrafusp alfa in just 2 patients with advanced bile duct cancer that had spread. The goal was to find the safest dose and see if the combo could help control the cancer. The study is no longer recruiting, and results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bintrafusp alfa (immunotherapy drug) and hypofractionated radiation therapy
- What this could lead to
- If it works, this could point toward a new combination treatment for advanced bile duct cancer that is hard to treat.
- What could go wrong
- This is a very early Phase 1 trial with only 2 patients, so results may not apply broadly. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action antibody boost chemo against bile duct cancer?
- New chemo combo targets Hard-to-Treat liver cancer
- Triple therapy takes on bile duct cancer: hope for unresectable cases
- New hope for advanced bile duct cancer: liver transplant after targeted radiation
- New chemo mist targets abdominal cancer with fewer side effects
- New drug targets bile duct cancer in small trial